Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Drugs and adverse drug reactions: how worried should we be?

Bates DW.

JAMA. 1998 Apr 15;279(15):1216-7. No abstract available.

PMID:
9555764
2.

Adverse drug reactions in hospitalized patients.

Hui KK.

JAMA. 1998 Nov 25;280(20):1742-3; author reply 1743-4. No abstract available.

PMID:
9842944
3.

Adverse drug reactions in hospitalized patients.

Hanzlick R, Baker PB, Hutchins GM.

JAMA. 1998 Nov 25;280(20):1742; author reply 1743-4. No abstract available.

PMID:
9842943
4.

Adverse drug reactions in hospitalized patients.

Bush T.

JAMA. 1998 Nov 25;280(20):1742; author reply 1743-4. No abstract available.

PMID:
9842942
5.

Adverse drug reactions in hospitalized patients.

Kravitz GR.

JAMA. 1998 Nov 25;280(20):1741; author reply 1743-4. No abstract available.

PMID:
9842941
6.

Adverse drug reactions in hospitalized patients.

Fremont-Smith K.

JAMA. 1998 Nov 25;280(20):1741; author reply 1743-4. No abstract available.

PMID:
9842940
7.

The importance of adverse reactions in drug regulation.

Dukes MN.

Drug Saf. 1990 Jan-Feb;5(1):3-6. No abstract available.

PMID:
2310512
8.

Safety of newly approved drugs: implications for prescribing.

Temple RJ, Himmel MH.

JAMA. 2002 May 1;287(17):2273-5. No abstract available.

PMID:
11980528
9.

Discovering adverse drug reactions.

Lasagna L.

JAMA. 1983 Apr 22-29;249(16):2224-5. No abstract available.

PMID:
6339764
10.

Analysis on 85 case reports of adverse drug reactions.

Jin XQ, Min LQ.

Afr J Tradit Complement Altern Med. 2013 Apr 12;10(3):508-12. eCollection 2013.

11.

FDA weighs communicating drug-related risk to patients.

Stephenson J.

JAMA. 1999 Aug 11;282(6):515. No abstract available. Erratum in: JAMA 1999 Oct 20;282(15):1425.

PMID:
10450699
12.

The case for deregulating drug efficacy.

Dorsey R.

JAMA. 1979 Oct 19;242(16):1755-60. No abstract available.

PMID:
480602
13.

The role of litigation in defining drug risks.

Kesselheim AS, Avorn J.

JAMA. 2007 Jan 17;297(3):308-11. No abstract available.

PMID:
17227983
14.

Unwanted drug effects: whose responsibility?

[No authors listed]

Lancet. 1979 Jul 7;2(8132):21. No abstract available.

PMID:
87894
15.

Post-marketing surveillance of prescription drug safety: past, present, and future.

Chen BK, Yang YT.

J Leg Med. 2013;34(2):193-213. doi: 10.1080/01947648.2013.800797. No abstract available.

PMID:
23980746
16.

New law in Germany compensates patients for drug side-effects.

Orellana C.

Lancet. 2002 Aug 10;360(9331):471. No abstract available.

PMID:
12241734
17.

Can postmarketing surveillance help to effect optimal drug therapy?

Strom BL, Melmon KL.

JAMA. 1979 Nov 30;242(22):2420-2.

PMID:
385922
18.

New drugs-miracles or mirages?

[No authors listed]

JAMA. 2014 Jan 22-29;311(4):423. doi: 10.1001/jama.2013.279299. No abstract available.

PMID:
24449329
19.

Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009.

Wu TY, Jen MH, Bottle A, Molokhia M, Aylin P, Bell D, Majeed A.

J R Soc Med. 2010 Jun;103(6):239-50. doi: 10.1258/jrsm.2010.100113.

20.

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Lazarou J, Pomeranz BH, Corey PN.

JAMA. 1998 Apr 15;279(15):1200-5.

PMID:
9555760
Items per page

Supplemental Content

Write to the Help Desk